Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key

摘要: Triple negative breast cancer (TNBC) accounts for 15%-20% of all cancer, and is still defined as what it not. Currently, TNBC the only type which there are no approved targeted therapies maximum tolerated dose chemotherapy with taxanes anthracycline-containing regimens standard care in both neoadjuvant adjuvant settings. In last years, metronomic (MC) being explored an alternative to improve outcomes TNBC. setting, purely hybrid approaches have been developed objective increasing complete pathologic response (pCR) prolonging disease free survival. These proved be very effective achieving pCR rates between 47%-60%, but at cost great toxicity. MC used intensify and, more promisingly, maintenance therapy high-risk patients, especially those after chemotherapy. Considering dismal prognosis TNBC, any strategy that potentially improves outcomes, specially oral agents broadly available inexpensive, should considered certainly warrants further exploration. Finally, benefit needs validated properly designed clinical trials were selection population key.